Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDCD1 | Q15116 | 4/20 | 0.36 |
| ▸ | CD274 | Q9NZQ7 | 4/20 | 0.36 |
| ▸ | PNMT | P11086 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 4/20 | 0.32 |
| ▸ | HTR2B | P41595 | 3/20 | 0.32 |
| ▸ | HTR2A | P28223 | 2/20 | 0.32 |
| ▸ | PDK1 | Q15118 | 3/20 | 0.31 |
| ▸ | FBP1 | P09467 | 2/20 | 0.31 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.31 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.31 |
| ▸ | MET | P08581 | 1/20 | 0.31 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL15021264 | 0.98 | PDCD1 (0.35) | PDCD1CD274PNMTDRD2PDE10A | |
| Hydrochloric Acid SCHEMBL7677012 | 0.98 | PDCD1 (0.35) | PDCD1CD274PNMTDRD2PDE10A | |
| SCHEMBL330205 | 0.86 | PDCD1 (0.44) | PDCD1CD274PNMTPDE10A | |
| SCHEMBL15910247 | 0.86 | PDCD1 (0.48) | PDCD1CD274PNMT | |
| Hydrochloric Acid SCHEMBL31569096 | 0.84 | PDCD1 (0.47) | PDCD1CD274PNMT | |
| Bromide SCHEMBL3822772 | 0.84 | PDCD1 (0.43) | PDCD1CD274PNMTPDE10A | |
| Hydrochloric Acid SCHEMBL6765448 | 0.84 | PDCD1 (0.43) | PDCD1CD274PNMTPDE10A | |
| SCHEMBL15007108 | 0.77 | DRD2 (0.33) | PDCD1CD274DRD2PDK1FBP1 | |
| SCHEMBL2666128 | 0.76 | — | — | |
| SCHEMBL171200 | 0.76 | PDK1 (0.54) | PDK1FBP1APOBEC3AAPOBEC3GNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230052191-A1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LTD (GB) | 2023-02-16 | — | — | US | disclosed |
| US-20220143042-A1 | FUSED GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2022-05-12 | — | — | US | disclosed |
| US-20200369658-A1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LTD (GB) | 2020-11-26 | — | — | US | disclosed |
| US-10774078-B2 | Compounds | MISSION THERAPEUTICS LTD (GB) | 2020-09-15 | — | — | US | disclosed |
| US-20190330202-A1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LTD (GB) | 2019-10-31 | — | — | US | disclosed |
| US-10392380-B2 | Compounds | MISSION THERAPEUTICS LIMITED (GB) | 2019-08-27 | — | — | US | disclosed |
| US-20180162852-A1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LIMITED | 2018-06-14 | — | — | US | disclosed |
| US-9926307-B2 | Compounds | MISSION THERAPEUTICS LTD (GB) | 2018-03-27 | — | — | US | disclosed |
| US-20170247365-A1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LTD (GB) | 2017-08-31 | — | — | US | disclosed |
| EP-2831074-B1 | NOVEL PYRAZOLOPYRIMIDINES AS METABOTROPIC GLUTAMATE 5 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PSYCHIATRIC DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2016-09-14 | — | — | EP | disclosed |
| US-20130150347-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-13 | — | — | US | disclosed |
| US-20130150341-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-13 | — | — | US | disclosed |
| US-20130150341-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-13 | — | — | US | disclosed |
| US-20130150347-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-13 | — | — | US | disclosed |
| US-20130143870-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-06 | — | — | US | disclosed |
| US-20130143870-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-06 | — | — | US | disclosed |
| US-20080161289-A1 | Fused Thiazole Derivatives Having Affinity for the Histamine H3 Receptor | GLAXO GROUP LIMITED | 2008-07-03 | — | — | US | disclosed |
| EP-1303521-B1 | TETRAHYDRO-HETEROCYCLOAZEPINYL PYRIMIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2005-02-02 | — | — | EP | disclosed |
| US-20020045635-A1 | Novel mGluR antagonists and a method for their synthesis | HOFFMANN-LA ROCHE, INC. | 2002-04-18 | — | — | US | disclosed |
| US-6369222-B1 | NITRO- AND CYANO-1,2,4,5-TETRAHYDRO-HETEROCYCLOAZEPINYL PYRIMIDINE DERIVATIVES; BRAIN, EYE, MUSCULAR, PSYCHOLOGICAL AND NERVOUS SYSTEM DISORDERS | HOFFMANN-LA ROCHE INC. | 2002-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130150341-A1 | NOVEL COMPOUNDS | GRM5, GRM1, GRIK5 | PDCD1 3998/4885CD274 3840/4885PNMT 826/4885 |
| US-10774078-B2 | Compounds | UCHL1, UCHL3, UCHL5 | PDCD1 878/4885CD274 1176/4885PNMT 3651/4885 |
| US-20020045635-A1 | Novel mGluR antagonists and a method for their synthesis | GRM1, GRM5, GRM2 | PDCD1 3508/4885CD274 4007/4885PNMT 308/4885 |
| US-20080161289-A1 | Fused Thiazole Derivatives Having Affinity for the Histamine H3 Receptor | HRH3, HRH4, HRH2 | PDCD1 1718/4885CD274 1101/4885PNMT 183/4885 |
| US-20180162852-A1 | NOVEL COMPOUNDS | UCHL1, UCHL3, UCHL5 | PDCD1 855/4885CD274 1059/4885PNMT 4019/4885 |
| US-20220143042-A1 | FUSED GLYCOSIDASE INHIBITORS | BACE1, ENGASE, GBA3 | PDCD1 4099/4885CD274 3725/4885PNMT 652/4885 |
| US-10392380-B2 | Compounds | UCHL1, UCHL3, UCHL5 | PDCD1 878/4885CD274 1176/4885PNMT 3651/4885 |
| US-20130150347-A1 | NOVEL COMPOUNDS | GRM5, GRM1, GRIK5 | PDCD1 3998/4885CD274 3840/4885PNMT 826/4885 |
| US-20200369658-A1 | NOVEL COMPOUNDS | UCHL1, UCHL3, UCHL5 | PDCD1 855/4885CD274 1059/4885PNMT 4019/4885 |
| US-20130143870-A1 | NOVEL COMPOUNDS | GRM5, GRM1, GRIK5 | PDCD1 3998/4885CD274 3840/4885PNMT 826/4885 |
| US-20190330202-A1 | NOVEL COMPOUNDS | UCHL1, UCHL3, UCHL5 | PDCD1 855/4885CD274 1059/4885PNMT 4019/4885 |
| US-20170247365-A1 | NOVEL COMPOUNDS | UCHL1, UCHL3, UCHL5 | PDCD1 855/4885CD274 1059/4885PNMT 4019/4885 |
| US-20230052191-A1 | NOVEL COMPOUNDS | UCHL1, UCHL3, UCHL5 | PDCD1 855/4885CD274 1059/4885PNMT 4019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.